Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jayon Lihm"'
Autor:
Adam J. Schoenfeld, Hira A. Rizvi, Danish Memon, Narek Shaverdian, Matthew J. Bott, Jennifer L. Sauter, C. Jillian Tsai, Jayon Lihm, David Hoyos, Andrew J. Plodkowski, Rocio Perez-Johnston, Peter Sawan, Jacklynn V. Egger, Benjamin D. Greenbaum, Andreas Rimner, Gregory J. Riely, Charles M. Rudin, Valerie W. Rusch, Daniel R. Gomez, Matthew D. Hellmann
Publikováno v:
Clinical Cancer Research. 28:3797-3803
Purpose: Clinical patterns and the associated optimal management of acquired resistance to PD-(L)1 blockade are poorly understood. Experimental Design: All cases of metastatic lung cancer treated with PD-(L)1 blockade at Memorial Sloan Kettering were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0028fe3841fff93e2b97cef720ffcb40
https://doi.org/10.1158/1078-0432.ccr-22-0657
https://doi.org/10.1158/1078-0432.ccr-22-0657
Autor:
Marta Łuksza, Zachary M. Sethna, Luis A. Rojas, Jayon Lihm, Barbara Bravi, Yuval Elhanati, Kevin Soares, Masataka Amisaki, Anton Dobrin, David Hoyos, Pablo Guasp, Abderezak Zebboudj, Rebecca Yu, Adrienne Kaya Chandra, Theresa Waters, Zagaa Odgerel, Joanne Leung, Rajya Kappagantula, Alvin Makohon-Moore, Amber Johns, Anthony Gill, Mathieu Gigoux, Jedd Wolchok, Taha Merghoub, Michel Sadelain, Erin Patterson, Remi Monasson, Thierry Mora, Aleksandra M. Walczak, Simona Cocco, Christine Iacobuzio-Donahue, Benjamin D. Greenbaum, Vinod P. Balachandran
Publikováno v:
Nature. 606:389-395
Cancer immunoediting1is a hallmark of cancer2that predicts that lymphocytes kill more immunogenic cancer cells to cause less immunogenic clones to dominate a population. Although proven in mice1,3, whether immunoediting occurs naturally in human canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65b02033b56c443b58e086f5f9943068
https://doi.org/10.1038/s41586-022-04735-9
https://doi.org/10.1038/s41586-022-04735-9
Publikováno v:
Cancer Research. 83:860-860
Retrotransposons are genetic elements that have the ability to copy and paste themselves in the genome via the proteins they encode. Since the rapid growth of a retrotransposon can be highly deleterious at the organismal level, many of these genetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::297bf5c7542fd5cb5b639f475347709e
https://doi.org/10.1158/1538-7445.am2023-860
https://doi.org/10.1158/1538-7445.am2023-860
Autor:
Jayon Lihm, Hyejin Choi, Mariam M. George, Yuval Elhanati, David Hoyos, Marta Luksza, Taha Merghoub, Benjamin D. Greenbaum
Publikováno v:
Cancer Research. 83:610-610
As tumors evolve, cancer cells acquire somatic mutations and these mutations generate tumor specific neoantigens that are different from self and can be recognized by T-cells, inducing anti-tumor immune responses. Such immunogenic antigens can be eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::738405409c18a3aea739af841a3e9e27
https://doi.org/10.1158/1538-7445.am2023-610
https://doi.org/10.1158/1538-7445.am2023-610
Autor:
Martin H Voss, Neil J. Shah, Hannah L Kalvin, Jayon Lihm, Hao Li, Ritesh R Kotecha, Irene Jarchum, Sai Vikram Vemula, Saurabh Gupta, Robert J. Motzer, Irina Ostrovnaya, Benjamin Greenbaum, A. Ari Hakimi
Publikováno v:
Journal of Clinical Oncology. 41:659-659
659 Background: Combination therapy with I/N can achieve long-term benefit in a sizable proportion of RCC pts, but broad application has been challenged by a high incidence of irAEs. Host features affecting antigen presentation are candidate determin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b28a9697236dc0da48a14eb4942b8da3
https://doi.org/10.1200/jco.2023.41.6_suppl.659
https://doi.org/10.1200/jco.2023.41.6_suppl.659
Autor:
Hira Rizvi, Fromm G, Chad M. Vanderbilt, Nicholas McGranahan, Mohsen Abu-Akeel, Pedro Beltrao, Benjamin D. Greenbaum, Umesh Bhanot, Taha Merghoub, Jia Luo, Martin L. Miller, Caroline G. McCarthy, Andrew Chow, Adam J. Schoenfeld, Andrew J. Plodkowski, Schreiber Th, Hellmann, Danish Memon, Jayon Lihm, Jennifer L. Sauter, Dajia Ye, Andy J. Minn, Cailian Liu, Marta Łuksza
Although cancer immunotherapy with PD-(L)1 blockade is now routine treatment for patients with lung cancer, remarkably little is known about acquired resistance. We examined 1,201 patients with NSCLC treated with PD-(L)1 blockade to clinically charac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f914f732ff2849d421a324b47269014b
https://doi.org/10.1101/2021.07.21.452854
https://doi.org/10.1101/2021.07.21.452854
Autor:
Michael Lattanzi, Alexander Solovyov, Jayon Lihm, Colleen Quinlan, Karissa Whiting, Hao Li, Hikmat A. Al-Ahmadie, Min Yuen Teo, David Henry Aggen, Irina Ostrovnaya, Ashley Marie Regazzi, Marwah Jihad, Dean F. Bajorin, Arjun Vasant Balar, Amir Mortazavi, Taha Merghoub, Gopa Iyer, Jonathan E. Rosenberg, Benjamin Greenbaum, Samuel Aaron Funt
Publikováno v:
Journal of Clinical Oncology. 40:4584-4584
4584 Background: We previously reported the clinical outcomes of a positive multi-center phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) plus atezolizumab (A) in patients with muscle-invasive bladder cancer (Funt, et al. JCO 2022). In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25fd13ea011ec8a12730a3546ec316c7
https://doi.org/10.1200/jco.2022.40.16_suppl.4584
https://doi.org/10.1200/jco.2022.40.16_suppl.4584
Autor:
Rebecca Yu, Christine A. Iacobuzio-Donahue, Abderezak Zebboudj, Kevin C. Soares, Zachary Sethna, Jayon Lihm, Alvin Makohon-Moore, Anthony J. Gill, Rajya Kappagantula, Adrienne Kaya Chandra, Vinod P. Balachandran, Benjamin D. Greenbaum, Erin Patterson, Masataka Amisaki, Zagaa Odgerel, Anton Dobrin, Amber L. Johns, Luis A. Rojas, Michel Sadelain, David Hoyos, Marta Łuksza, Joanne Leung, Pablo Guasp
Publikováno v:
Cancer Research. 81:PR-003
Cancer immunoediting is a hallmark of cancer that predicts T cells recognize and kill tumor cells expressing immunogenic mutations (neoantigens), to induce less immunogenic clones to outgrow in tumors. Although established through longitudinal studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2080f08395f6632016a02b325fa503c3
https://doi.org/10.1158/1538-7445.panca21-pr-003
https://doi.org/10.1158/1538-7445.panca21-pr-003
Autor:
Pablo Guasp, Adrienne Kaya Chandra, Abderezak Zebboudj, Joanne Leung, Rajya Kappagantula, Marta Luksza, Rebecca Yu, Christine A. Iacobuzio-Donahue, Amber L. Johns, Michel Sadelain, David Hoyos, Erin Patterson, Luis A. Rojas, Antony Gill, Masataka Amisaki, Zagaa Odgerel, Vinod P. Balachandran, Benjamin Greenbaum, Jayon Lihm, Anton Dobrin, Kevin C. Soares, Alvin Makohon-Moore, Zachary Sethna
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A862-A862
BackgroundCancer immunoediting predicts that T cells selectively kill tumor cells expressing immunogenic mutations (neoantigens) resulting in less immunogenic clones to outgrow in tumors.1 Although established through longitudinal studies of how tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::646b1913ecc8687d260ed1216a077dc8
https://doi.org/10.1136/jitc-2021-sitc2021.824
https://doi.org/10.1136/jitc-2021-sitc2021.824
Autor:
Alvin M. Moore, Zachary Sethna, Erin Patterson, Jayon Lihm, Vinod P. Balachandran, Rajya Kappagantula, David Hoyos, Luis A. Rojas, Marta Luksza, Benjamin D. Greenbaum, Christine A. Iacobuzio-Donahue, Kevin C. Soares, Yuval Elhanati
Publikováno v:
Cancer Research. 81:LB005-LB005
Cancer immunoediting, a hallmark of cancer, predicts that lymphocytes recognize tumor-specific mutations (neoantigens) to kill immunogenic tumor cells and select less immunogenic clones to survive in immunocompetent hosts. Yet, though proven in mice,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb7a7038ffafa4b6d4288edb42e8d898
https://doi.org/10.1158/1538-7445.am2021-lb005
https://doi.org/10.1158/1538-7445.am2021-lb005